Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EORTC 40091 perioperative mFOLFOX6 with or without bevacizumab or panitumumab for resectable colorectal liver metastases
NL-OMON39488Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid, bevacizumab and panitumumab in colorectal cancer (CRC), sponsored by European Organisation for Research and Treatment of Cancer. Started Jan 2015; status: active, not recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acidbevacizumabpanitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON39488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39488.